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Design and Engineering of Trastuzumab Emtansine production plant
Part III: Upstream, Bioreactions and Fermentation of the antitumorigenic agent Ansamitocin P3. 
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ANSAMITOCIN BIOSYNTHESIS METABOLIC PATHWAY
EXONENTIAL FED-BATCH SIMULATION
BIOREACTOR AND CONTROL SCALE-UP AND FERMENTATION
SUPERPRO STOICHIOMETRIC BIOREACTION
Actinosynnema pretiosum
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• In order to optimize the process the downstream hardware has reduced the
volume.
• Gant Chart development allows to design a semicontinue process in the
downstream, starting new batches 3 days spaced.
• Fermentation seems to be the limiting stage as it lasts longer. 5 reactors run at the
same time.
• Trastuzumab production is the slowest process. Its analysis involve DM1
production analysis.
• Both fermentations last the same (not complete processes).
• 105 batches can be done by year.
• Mixing part shared by both bioprocesses.
• Actinosynnema genre known for a “synnemata” structure -
formation.
• Described in 1978 is an Actinomycetales type bacteria.
• Gram +, catalase positive, mesophilic and aerobic bacteria.
• Secondary metabolites produced as antibiotics.
• 8131572 bp linear genome. 2 gene clusters are found for
ansamitocin P3 production, containing 51 ORFs. Clusters are
spaced within 30 Kpb.
• Ribosomal subunits: 5s, 16s and 23s.
• Can be grown under submerged culture conditions.
• Stoichiometric reaction is needed for the simulation with SuperPro Designer®.
• With element balances and bibliographic data the reaction can be defined.
• Stoichiometric molar balance matrix is generated and solved.
• C source  Glucose N source  Ammonia Cl source  Sodium Chloride
Element balances generated
Bibliographic data
Matrix formation 
and solution
Final stoichiometric reaction
Sartorius® stainless steel bioreactor (600 L) used in this process. 480 L (useful volume).
Característics:
• Higher final product concentrations than normal fed-batch culture (0,3 g/L)
• Specific growth rate control µ = 0,02 h-1.
• Simulation can differ from the real situation: Transport phenomena limitations,
metabolic variations…
 BioPat® controls: SIP (Sterilization In Place), agitation system, temperature control system, exhaust
cooler/heater, pressure control valve, T control system, pH control system, gas inlet line, sample
analysis system.
 DCU: Intelligent control unit.
 Biostat®: Support portfolio unit Important to control the biomass evolution in order to 
act against external disturbances (Regulation control)
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Breast cancer is the most common cancer among women following skin cancer. Specifically, HER2 overexpressing tumours
reveal a particularly poor prognosis. For this reason, the aim of this project is to simulate an industrial plant for the production of
the antibody drug conjugate Trastuzumab emtansine (T-DM1) which has resulted to be a good therapy for this type of breast
cancer. T-DM1 is composed by a monoclonal antibody (Trastuzumab) produced in CHO DG44 cells and a cytotoxic drug (DM1)
produced in Actinosynnema pretiosum. Therefore, two parallel processes have been designed to produce these two
components followed by a mixing step. All simulations have been done using SuperPro Designer. This part, is focused on the
upstream and bioreaction of the DM1 process with metabolic biosynthesis studies and fermentation simulation.
ANSAMITOCIN TYPES
PARAMETERS
ABSTRACT
• Scale up process is developed in
order to achieve the correct
biomass concentration in the final
fermentator.
• The inoculums should be 10% of
the next reactor volume.
• Medium is sterilized before
entering any tank.
Graphic 1: Simulation variables evolution in time (Results).
Figure 9: Fed-batch bioreactor scheme
Figure 1: Gant chart process  for Trastuzumab (limiting bioprocess).
-T = 28ºC
-pH = 6,5
-Agitation: 170 
rpm
-Aeration : 1 vvm
-Dissolved 
oxygen: 30 %
MEDIUM
Defined medium : 
- Dextrin   
- Porflo
- CSP         
- CaCO3       
- K2HPO4
- Isobutanol
- CoCl2·6H2O
- SAG 471
- FeSO4·7H2O
- Maltose
Final biomass concentration:
105 g/L
Final ansamitocin concentration:
0,36 g/L
-Maytansine variant.
-Antibiotic properties with effects in 
human organisms.
-It inhibits microtubules assembly.
-Ansamitocin 
variations 
depend on 
the residues
Figure 2: Ansamitocin variations depending on the 
residue. (Cassady et al., 2004)
Figure 3: Actinosynnema 
synnemata (Labeda, 2015)
Figure 4: Actinobacteria myeclia
(Wikipedia CC, Creative Commons)  
Figure 5: Ansamitocin P3 gene cluster in Actinosynnema Pretiosum (Kang, Shen and Bai, 2012)
Figure 10: Sartorius® stainless steel bioreactor
Figure 11: Biomass control scheme 
Figure 12: Upstream, scale up and fermentator ( Ansamitocin process)
1st): AHBA synthesis.
• AHBA synthesis, described in Am. mediterranei
S699 sare (Rifamycin production)
• asm23, 22, 24, 43, 44, 45 i 47 genes involved.
• PEP + C source + N source AHBA percusor.
• Genes in clúster 1 mostly involved.
Figure 6: AHBA synthesis (Cassady et al., 2004).
2nd): Polyketide chain formation
• PKS (Polyketide synthase) adds different
organic groups into the AHBA precursor.
• Complicate step (glycolate unit addition)
involve other asm genes.
• PKS: Multienzymatic complex (1300 kDa)
formed by 4 chains (asm A, asmB, asm C
and asmD) with different activities involving
ACP ligase, β-ketoacyl-ACP synthase, enoil
reductase and others.
• Genes in clúster 2 involved.
Figure 7: Polyketide chain formation, mediated by PKS
(Kang, Shen and Bai, 2012)
3rd): Post 
polyketide 
modifications
• asm 9 catalyzes 
the polyketide 
cyclization.
• They give rise to 
the final product 
ansamitocin P3.
Figure 8: Post polyketide modifications for 
ansamitocin P3 production
(Kang, Shen and Bai, 2012)
13,68 kg
of DM1
produced
by year.
